Capricor Therapeutics (CAPR) Accounts Payables: 2011-2025
Historic Accounts Payables for Capricor Therapeutics (CAPR) over the last 15 years, with Sep 2025 value amounting to $2.7 million.
- Capricor Therapeutics' Accounts Payables fell 58.36% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 58.36%. This contributed to the annual value of $3.3 million for FY2024, which is 47.46% down from last year.
- Latest data reveals that Capricor Therapeutics reported Accounts Payables of $2.7 million as of Q3 2025, which was down 43.49% from $4.8 million recorded in Q2 2025.
- Capricor Therapeutics' Accounts Payables' 5-year high stood at $6.8 million during Q3 2023, with a 5-year trough of $2.7 million in Q3 2025.
- Its 3-year average for Accounts Payables is $5.3 million, with a median of $5.4 million in 2023.
- Per our database at Business Quant, Capricor Therapeutics' Accounts Payables spiked by 167.63% in 2021 and then crashed by 58.36% in 2025.
- Quarterly analysis of 5 years shows Capricor Therapeutics' Accounts Payables stood at $3.1 million in 2021, then surged by 55.14% to $4.8 million in 2022, then increased by 29.28% to $6.3 million in 2023, then crashed by 47.46% to $3.3 million in 2024, then tumbled by 58.36% to $2.7 million in 2025.
- Its Accounts Payables was $2.7 million in Q3 2025, compared to $4.8 million in Q2 2025 and $5.3 million in Q1 2025.